priors.science/reviews/atopic-dermatitis-pharmacotherapy

Atopic Dermatitis Pharmacotherapy

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
Weeklyre-scored against new papers
6 Established · 11 Likely · 3 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableDupilumab EASI-75 in moderate-to-severe atopic dermatitisDupilumab EfficacyEstablished89%20
StableUpadacitinib EASI-75 in atopic dermatitisJAK Inhibitor EfficacyEstablished89%20
StableLebrikizumab EASI-75 in atopic dermatitisIl13 InhibitionEstablished86%20
StableRuxolitinib cream EASI reduction in atopic dermatitisTopical JAK InhibitorsEstablished86%18
StableRuxolitinib cream itch relief versus vehicleTopical JAK InhibitorsEstablished86%20
StableNemolizumab pruritus reduction in atopic dermatitisIl31 PathwayEstablished86%20
StableDupilumab itch reduction in atopic dermatitisDupilumab EfficacyLikely84%20
StableIL-13 inhibitors quality of life in atopic dermatitisIl13 InhibitionLikely84%20
StableAbrocitinib rapid itch relief in atopic dermatitisJAK Inhibitor EfficacyLikely82%20
StableJAK inhibitors dose-dependent efficacy in atopic dermatitisJAK Inhibitor EfficacyLikely78%20
StableUpadacitinib versus dupilumab EASI-75Head To Head ComparisonsLikely78%20
StableDupilumab drug survival versus conventional systemicsHead To Head ComparisonsLikely76%20
StableDupilumab long-term efficacy over 52 weeksDupilumab EfficacyLikely75%20
StableTralokinumab IGA clearance in atopic dermatitisIl13 InhibitionLikely75%20
StableNemolizumab sleep improvement in atopic dermatitisIl31 PathwayLikely72%20
StableCyclosporin versus methotrexate in atopic dermatitisConventional SystemicsLikely71%20
StableDupilumab efficacy with comorbid asthmaDupilumab EfficacyLikely70%19
StableJAK inhibitor major adverse cardiovascular event risk is age-dependent in atopic dermatitisJAK Inhibitor SafetyUncertain61%20
StableMethotrexate long-term efficacy in atopic dermatitisConventional SystemicsUncertain56%20
StableJAK inhibitor venous thromboembolism risk in atopic dermatitisJAK Inhibitor SafetyUncertain42%20
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic